Prostaglandin E1 for Diabetic Peripheral Neuropathy: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

LI Ya ¹ , FANG Dijin ² , GAO Xia ² ,  TIAN Haoming ¹ , WU Taixiang ³

1.Department of Endocrinology and Metabolism，West China Hospital，Sichuan University， Chengdu 610041, China 2. Affiliated Hospital of Yan’an University，Yan’an 716000, China 3. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, Chin;

Corresponding author：

TIAN Haoming, Email: hmtian999@yahoo.com.cn

Keywords：

Diabetes; Diabetic peripheral neuropathy; Prostaglandin E1; Systematic review

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective　 To evaluate the efficacy and safety of prostaglandin E1 (PGE1) for diabetic peripheral neuropathy (DPN).
Methods 　We searched the Cochrane Library, PubMed, EMbase, CNKI, VIP and handsearched Chinese Journal of Metabolism, Chinese Journal of Diabetes and New Chinese Medicine. Randomized controlled trials of clinical therapeutic studies on PGE1 for DPN were included. The quality of included studies was evaluated and Meta-analysis was performed.
Results 　Thirty-one trials involving 2 497 participants were included. Meta-analysis indicated that PGE1 was more effective than Vitamin B, Placebo and other microcirculation improving drugs in improving symptoms and signs of DPN. The RR (95%CI) were ［RR=1.75, 95％CI (1.54, 2.00)］, ［RRpooled=1.57, 95％CI (1.42, 1.74)］and［RR=1.31, 95％CI (1.19, 1.45)］respectively. PGE1 was more effective than Vitamin B, Placebo and other microcirculation improving drugs in improving nerve conduction velocity (NCV) of DPN patients. For spontaneous pain and hypesthesia of DPN patients, Lipo-PGE1 was more effective compared with PGE1-CD and the RR (95%CI) was［RR=1.43, 95％CI (1.16, 1.76)］. Slight adverse effects were reported in 16 studies.
Conclusion　 Based on this review, PGE1 is effective for DPN. However, the evidence is not b enough due to the low quality of included trials. Further large-sample and multi-center studies are needed.

Citation： LI Ya,FANG Dijin,GAO Xia,TIAN Haoming,WU Taixiang. Prostaglandin E1 for Diabetic Peripheral Neuropathy: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2006, 06(6): 404-415. doi: Copy

1.	谭元菊，安峥. 前列地尔治疗糖尿病性周围神经病变的临床研究. 中国医院用药评价与分析，2004；4(3) :175~177.
2.	刘玉春，向光大，乐岭等. 前列腺素E1对糖尿病周围神经病变的疗效观察. 中国综合临床，2000；6(16) :427~428.
3.	杨斌，徐广珍，吴丽华等. E1注射液治疗糖尿病周围神经病变的疗效观察. 中国基层医药，2002; 9(1) :8~9.
4.	宋文娟，王华，余清等. 凯时治疗糖尿病性周围神经病变临床研究. 中华综合医学，2002；3(2)：116~118.
5.	黄耀忠，胡斌. 前列腺素E1治疗糖尿病周围神经病变35例疗效观察. 广东医学，2002；23(9)：980~981.
6.	尤巧英, 李益明, 周丽诺等. 凯时治疗糖尿病周围神经病变临床研究. 中国新药杂志，2000；9(7)：471~473.
7.	吕爱玲，阮爱兵. 前列地尔治疗糖尿病神经病变33例临床观察. 临床荟萃，2004; 19(8) :459~460.
8.	吴伟琼，刘伟芳，许美伦等, 凯时与甲钴胺联合治疗糖尿病周围神经病变. 河北医学, 2005.11(5):411~413.
9.	王莉. 前列腺素E1治疗糖尿病周围神经病变的疗效观察. 安徽医学, 2004; 25(1): 62~64.
10.	黄雌友，姚伟峰. 前列腺素E1治疗糖尿病周围神经病变的效果观察. 齐齐哈尔医学院学报, 2002；23(10): 1126~1127.
11.	姚军，刘巍. 前列腺素E1治疗糖尿病周围神经病变疗效观察. 湖北省卫生职工医学院学报, 2004;17(1): 48~50.
12.	王志宏，张萍，沈绚梅等，前列腺素E1治疗糖尿病周围神经病变56例观察. 中国医师杂志, 2003,(9) :1287.
13.	谭元菊，安峥. Lipo PGE1对糖尿病周围神经病变及糖尿病肾病的治疗作用. 中日友好医院学报, 2004; 18(4) 223~226.
14.	谭宗章. 前列腺素E1治疗糖尿病周围神经病变40例疗效观察. 实用神经疾病杂志, 2004;7(6): 78~79.
15.	刘应兰，肖晓岚，刘江华等. Lipo- PGE1治疗糖尿病周围神经病变32例. 南华大学学报(医学版), 29(6):584~585.
16.	郝建平，颜文盛，曾维新等. 前列地尔脂微球载体联合甲钴胺治疗糖尿病周围神经病变——附40例报告. 新医学，2004；35(9):545~547.
17.	徐文华，万长秀，张汉祥，等. 前列地尔治疗糖尿病性周围神经病变20例. 医药导报, 2001; 20(12): 755~756.
18.	应卫婵. 前列腺素E1治疗糖尿病周围神经病变疗效观察. 浙江临床医学, 2002, 4(12): 913~914.
19.	钟国连，吕维名.前列腺素E1＋甲钴胺治疗糖尿病周围神经病变疗效观察. 赣南医学院学报, 2002, 22(4): 343~345.
20.	魏则文 ,杨慧英. 凯时治疗糖尿病周围神经病变观察. 辽宁实用糖尿病杂志, 2003; 11(1): 35~36.
21.	莫文，王建英. 前列地尔治疗老年2型糖尿病周围神经病变的疗效观察. 重庆医学, 2003; 32(9) :1272~1273.
22.	梁干雄，吴伟英. 小剂量保达新联合治疗糖尿病痛性神经病变临床观察. 广州医药, 2003;34(5): 44~45.
23.	米延起，刘燕，林海荣，等. 前列地尔治疗糖尿病周围神经病变30例分析. 中国药物与临床, 2004; 4(5):371~372.
24.	张秀坤. 前列地尔治疗糖尿病性周围神经病变 (附22例临床观察). 黑龙江医学, 2004;28(6): 419~421.
25.	李小飞，苏如婷. 前列腺素E1联合甲钴胺治疗糖尿病周围神经病变疗效观察. 右江医学, 2004; 35(3):54~55.
26.	吴修信，黄志勇. 前列地尔治疗糖尿病性神经损害的临床研究. 中华综合医学, 2002,3(4) :338~339.
27.	余芳，刘阁玲，李伟娟. 凯时治疗糖尿病周围神经病变疗效观察. 医学理论与实践, 2004; 8(17): 903~904.
28.	刘娟，张燕，席平. 前列腺素E1治疗糖尿病周围神经病变疗效观察. 中国综合临床, 2004,11(20).1003~1005.
29.	钟惠菊，韩秀云，方育川，等，前列腺素E1对糖尿病周围神经病变的疗效观察. 实用糖尿病杂志，1994；2(1)：33~34.
30.	张蜀平. 弥可保对糖尿病周围神经病变治疗作用的研究研究. 中华内分泌代谢杂志，1998；14（2）：130.
31.	Aszmann O, Tassler PL, Dellon AL. Changing the natural history of diabetic neuropathy: incidence of ulcer/amputation in the contralateral limb of patients with a unilateral nerve decompression procedure. Ann Plast Surg, 2004; 53(6): 517-522.
32.	Pham HT, Rich J, Veves A. Wound healing in diabetic foot ulceration: a review and commentary. Wounds, 2000(12): 79-81.
33.	Miejer JW, Bosma E, Lefrandt JD, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care, 2003; 26(3): 697-701.
34.	Ziegler, D. Polyneuropathy in the diabetic patient--update on pathogenesis and management. Nephrol Dial Transplan, 2004; 19(9): 2170-2175.
35.	Toyota T, Hirata Y, Ikeda Y, et al. Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins, 1993; 46(5): 453-468.
36.	Akahori H, Takamura T, Hayakawa T, et al. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality. Diabetes Res Clin Pract, 2004; 64(3): 153-159.
37.	Tan YJ, An Z. Clinical Study of the Efficacy of Lipo-PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Evaluation and analyisis of dr μg-use in hospitals of China, 2004; 4(3): 175-177.
38.	Liu YC, Xiang GD, Le L, et al. Study of the Efficacy of Lipo-PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Clinical Medicine of China, 2000; 6(16): 427-428.
39.	Yang B, Xu GZ, Wu LH, et al. Observation on Efficacy of PGE1 in Treating Peripheral Neuropathy in diabetes. Chinese Journal of Primary Medicine and Pharmacy, 2002; 9(1): 8-9.
40.	Song WJ, Wang H, Yu Q, et al. Study of the Efficacy of Lipo-PGE1 in the Treatment of Diabetic Peripheral Neuropathy. China Synthesis Medicine, 2002; 3(2): 116-118.
41.	Huang YZ, Hu B. Clinical Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy with 35 participants. Guangdong Medical Journal, 2002; 23(9): 980-981.
42.	You QY, Li YM, Zhou LN, et al. Study of the Efficacy of Lipo-PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Chinese Journal of New Dr μgs, 2000,9(7). 471-473.
43.	Lv AL, Yuan AB, Clinical Study of the Efficacy of PGE1 in the Treatment of Diabeetic Peripheral Neuropathy with 33 participants. Clinical Focus, 2004; 19(8): 459-460.
44.	He H, Liu QN. Wang HF, et al. Prostaglangin E1 and Danshen in treating Diabetic Peripheral Neuropathy in the elderly. Chinese Journal of Clinical Rehabilitation, 2003; 7(18): 2561-2562. 何华，刘齐宁，王惠芳等. 中药联合前列腺素E1改善老年2型糖尿病周围神经症状的疗效观察. 中国临床康复，2003; 7(18) :2561~2562.
45.	Wu WQ, Liu WF, Xu ML, et al. Clinical Observation of Combined Therapeutic Effect of Lipo-PGE1 and Mecobalam on Diabetic Peripheral Neuropathy. HeBei Medical Journal, 2005.11(5):411-413.
46.	Wang L. Clinical Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Anhui Medical Journal, 2004; 25(1) :62-64.
47.	Huang CY, Yao WF, Clinical Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Journal of Qiqihar Medical College, 2002; 23(10): 1126-1127.
48.	Yao J, Liu W, Observation on Efficacy of PGE1 in Treating Peripheral Neuropathy in diabetes. Journal of Hubei Medical Staff College, 2004; 17(1): 48-50.
49.	Wang ZH,, Zhang P, Shen XM, et al. Clinical Study of the Efficacy of PGE1 in the Treatment of Diabeetic Peripheral Neuropathy with 56 participants. Journal of Chinese Physician, 2003; 5(9)1287.
50.	Tan YJ, An Z. Efficacy of Lipo-PGE1 injection on Diabetic Nephropathy and Neuropathy. Journal of Chinese-Japan Friendship Hospital, 2004; 18(4) 223-226.
51.	Tan ZZ. Clinical Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy with 40 participants. Journal of Practical Nervous Diseases, 2004; 7(6): 78-79.
52.	Liu YL, Xiao XL, Liu JH, et al, Observation on Efficacy of. Lipo-PGE1 in Treating Peripheral Neuropathy in diabetes with 32 participants. Journal of NanHua University (Medical Edition), 2001; 29(6):584-585.
53.	Hao JP, Yan WS, Zeng WX, et al. Observation of Combined Therapeutic Effect of Lipo-PGE1 and Mecobalam on Diabetic Peripheral Neuropathy with 40 participants. New Chinese Medicine. 2004; 35(9):545-547.
54.	Xu WH, Wan CX, Zhang HX, et al. Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy with 20 participants. Herald of Medicine, 2001; 20(12): 755-756.
55.	Ying WC, Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Zhejiang Clinical Medical Journal, 2002; 4(12): 913-914.
56.	Zhong GL, Lv WM, A Clinical Observation of Lipo-PGE1 and Mecobalamin in the Treatment of Diabetic Peripheral Neuropathy. Journal of Gannan Medical College. 2002, 22(4): 343-345.
57.	Wei ZW, Yang HY. A Clinical Observation of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Liaoning Journal of Practical Diabetology. 2003.11(1):35-36.
58.	Mo W, Wang JY. Alprostadil in treating Diabetic Peripheral Neuropathy in the elderly. Chongqing Medical Journal, 2003;32(9): 1272-1273.
59.	Liang GX, Wu WY, Clinical Study of the Efficacy of PGE1 in the Treatment of Diabetic Painful Neuropathy. Journal of Guangzhou Medicine, 2003; 34(5): 44-45.
60.	` Mi YQ, Liu y, Lin HR, et al. Therapeutic Effect of Lipo-PGE1 on Diabetic Peripheral Neuropathy with 30 participants. Chinese Remedies and Clinics. 2004; 4(5): 371-372.
61.	Zhang XK. Alprostadil in treating Diabetic Peripheral Neuropathy with 22 participants. Heilongjiang Medical Journal, 2004; 28(6): 419-421.
62.	Li XF, Su RT, Observation of Combined Therapeutic Effect of Lipo-PGE1 and Mecobalam on Diabetic Peripheral Neuropathy. Youjiang Medical Journal. 2004; 35(3):54-55.
63.	Wu XX, Huang ZY, Clinical Study of PGE1 in the Treatment of Diabetic Neuropathy. China Synthetical Medicine, 2002, 3(4) :338-339.
64.	` Yu F, Liu GL, Li WJ. A Clinical Observation of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Journal of Medical Theory and practice, 2004; 8(17): 903-904.
65.	Liu J, Zhang Y, Xi P. Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Clinical Medicine of China, 2004; 11(20):1003-1005.
66.	Low PA. Autonomic neuropathies. Curr Opin Neurol, 2002; 15(5): 605-609.
67.	Zochodne DW. Nerve and ganglion blood flow in diabetes: an appraisal. Int Rev Neurobio, 2002; (50): 161-202.
68.	Meyer FP. Polyneuropathy–therapy. Dtsch Med Wochenschr. 2003; 128(11): 572.
69.	Shindo H, Tawata M, Inoue M, et al. The effect of prostaglandin E1 CD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy. Diabetes Res Clin Pract, 1994, 24(3):173-180.
70.	Carlson LA, Olsson AG. Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet, 1976; 9(7886):810.
71.	Zhong HJ, Han XY, Fang YC, et al. Study of the Efficacy of Lipo-PGE1 in the Treatment of Diabetic Peripheral Neuropathy Journal of Practical Diabetology, 1994; 2(1): 33-34.
72.	Yasutoshi I, Tadashi Y. The therapeutic effect of Lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors. Prostaglandins and other Lipid Mediators, 2001; (66): 221-234-667.
73.	Watanabe T, Kaji R, Oka N, et al. Ultra-high dose methyl-cobalamin promotes nerve regeneration in experimental acrylamide neuropathy. J neurol Sci, 1994; 122(2): 140-143.
74.	Zhang SP, A Clinical Study of Methycobal in the Treatment of Diabetic Peripheral Neuropathy. Chinese Journal of Endocrinology and Metabolism, 1998; 14(2): 130.
75.	Dyck PJ, Obrien PC. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care, 1989; 12(9): 649-652.
76.	Nagai Y, S μgiyama Y, Abe T, et al. 4-g Monofilament is clinically useful for detecting diabetic peripheral neuropathy. Diabetes Care, 2001; 24(1): 183-184.

1. 谭元菊，安峥. 前列地尔治疗糖尿病性周围神经病变的临床研究. 中国医院用药评价与分析，2004；4(3) :175~177.
2. 刘玉春，向光大，乐岭等. 前列腺素E1对糖尿病周围神经病变的疗效观察. 中国综合临床，2000；6(16) :427~428.
3. 杨斌，徐广珍，吴丽华等. E1注射液治疗糖尿病周围神经病变的疗效观察. 中国基层医药，2002; 9(1) :8~9.
4. 宋文娟，王华，余清等. 凯时治疗糖尿病性周围神经病变临床研究. 中华综合医学，2002；3(2)：116~118.
5. 黄耀忠，胡斌. 前列腺素E1治疗糖尿病周围神经病变35例疗效观察. 广东医学，2002；23(9)：980~981.
6. 尤巧英, 李益明, 周丽诺等. 凯时治疗糖尿病周围神经病变临床研究. 中国新药杂志，2000；9(7)：471~473.
7. 吕爱玲，阮爱兵. 前列地尔治疗糖尿病神经病变33例临床观察. 临床荟萃，2004; 19(8) :459~460.
8. 吴伟琼，刘伟芳，许美伦等, 凯时与甲钴胺联合治疗糖尿病周围神经病变. 河北医学, 2005.11(5):411~413.
9. 王莉. 前列腺素E1治疗糖尿病周围神经病变的疗效观察. 安徽医学, 2004; 25(1): 62~64.
10. 黄雌友，姚伟峰. 前列腺素E1治疗糖尿病周围神经病变的效果观察. 齐齐哈尔医学院学报, 2002；23(10): 1126~1127.
11. 姚军，刘巍. 前列腺素E1治疗糖尿病周围神经病变疗效观察. 湖北省卫生职工医学院学报, 2004;17(1): 48~50.
12. 王志宏，张萍，沈绚梅等，前列腺素E1治疗糖尿病周围神经病变56例观察. 中国医师杂志, 2003,(9) :1287.
13. 谭元菊，安峥. Lipo PGE1对糖尿病周围神经病变及糖尿病肾病的治疗作用. 中日友好医院学报, 2004; 18(4) 223~226.
14. 谭宗章. 前列腺素E1治疗糖尿病周围神经病变40例疗效观察. 实用神经疾病杂志, 2004;7(6): 78~79.
15. 刘应兰，肖晓岚，刘江华等. Lipo- PGE1治疗糖尿病周围神经病变32例. 南华大学学报(医学版), 29(6):584~585.
16. 郝建平，颜文盛，曾维新等. 前列地尔脂微球载体联合甲钴胺治疗糖尿病周围神经病变——附40例报告. 新医学，2004；35(9):545~547.
17. 徐文华，万长秀，张汉祥，等. 前列地尔治疗糖尿病性周围神经病变20例. 医药导报, 2001; 20(12): 755~756.
18. 应卫婵. 前列腺素E1治疗糖尿病周围神经病变疗效观察. 浙江临床医学, 2002, 4(12): 913~914.
19. 钟国连，吕维名.前列腺素E1＋甲钴胺治疗糖尿病周围神经病变疗效观察. 赣南医学院学报, 2002, 22(4): 343~345.
20. 魏则文 ,杨慧英. 凯时治疗糖尿病周围神经病变观察. 辽宁实用糖尿病杂志, 2003; 11(1): 35~36.
21. 莫文，王建英. 前列地尔治疗老年2型糖尿病周围神经病变的疗效观察. 重庆医学, 2003; 32(9) :1272~1273.
22. 梁干雄，吴伟英. 小剂量保达新联合治疗糖尿病痛性神经病变临床观察. 广州医药, 2003;34(5): 44~45.
23. 米延起，刘燕，林海荣，等. 前列地尔治疗糖尿病周围神经病变30例分析. 中国药物与临床, 2004; 4(5):371~372.
24. 张秀坤. 前列地尔治疗糖尿病性周围神经病变 (附22例临床观察). 黑龙江医学, 2004;28(6): 419~421.
25. 李小飞，苏如婷. 前列腺素E1联合甲钴胺治疗糖尿病周围神经病变疗效观察. 右江医学, 2004; 35(3):54~55.
26. 吴修信，黄志勇. 前列地尔治疗糖尿病性神经损害的临床研究. 中华综合医学, 2002,3(4) :338~339.
27. 余芳，刘阁玲，李伟娟. 凯时治疗糖尿病周围神经病变疗效观察. 医学理论与实践, 2004; 8(17): 903~904.
28. 刘娟，张燕，席平. 前列腺素E1治疗糖尿病周围神经病变疗效观察. 中国综合临床, 2004,11(20).1003~1005.
29. 钟惠菊，韩秀云，方育川，等，前列腺素E1对糖尿病周围神经病变的疗效观察. 实用糖尿病杂志，1994；2(1)：33~34.
30. 张蜀平. 弥可保对糖尿病周围神经病变治疗作用的研究研究. 中华内分泌代谢杂志，1998；14（2）：130.
31. Aszmann O, Tassler PL, Dellon AL. Changing the natural history of diabetic neuropathy: incidence of ulcer/amputation in the contralateral limb of patients with a unilateral nerve decompression procedure. Ann Plast Surg, 2004; 53(6): 517-522.
32. Pham HT, Rich J, Veves A. Wound healing in diabetic foot ulceration: a review and commentary. Wounds, 2000(12): 79-81.
33. Miejer JW, Bosma E, Lefrandt JD, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care, 2003; 26(3): 697-701.
34. Ziegler, D. Polyneuropathy in the diabetic patient--update on pathogenesis and management. Nephrol Dial Transplan, 2004; 19(9): 2170-2175.
35. Toyota T, Hirata Y, Ikeda Y, et al. Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins, 1993; 46(5): 453-468.
36. Akahori H, Takamura T, Hayakawa T, et al. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality. Diabetes Res Clin Pract, 2004; 64(3): 153-159.
37. Tan YJ, An Z. Clinical Study of the Efficacy of Lipo-PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Evaluation and analyisis of dr μg-use in hospitals of China, 2004; 4(3): 175-177.
38. Liu YC, Xiang GD, Le L, et al. Study of the Efficacy of Lipo-PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Clinical Medicine of China, 2000; 6(16): 427-428.
39. Yang B, Xu GZ, Wu LH, et al. Observation on Efficacy of PGE1 in Treating Peripheral Neuropathy in diabetes. Chinese Journal of Primary Medicine and Pharmacy, 2002; 9(1): 8-9.
40. Song WJ, Wang H, Yu Q, et al. Study of the Efficacy of Lipo-PGE1 in the Treatment of Diabetic Peripheral Neuropathy. China Synthesis Medicine, 2002; 3(2): 116-118.
41. Huang YZ, Hu B. Clinical Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy with 35 participants. Guangdong Medical Journal, 2002; 23(9): 980-981.
42. You QY, Li YM, Zhou LN, et al. Study of the Efficacy of Lipo-PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Chinese Journal of New Dr μgs, 2000,9(7). 471-473.
43. Lv AL, Yuan AB, Clinical Study of the Efficacy of PGE1 in the Treatment of Diabeetic Peripheral Neuropathy with 33 participants. Clinical Focus, 2004; 19(8): 459-460.
44. He H, Liu QN. Wang HF, et al. Prostaglangin E1 and Danshen in treating Diabetic Peripheral Neuropathy in the elderly. Chinese Journal of Clinical Rehabilitation, 2003; 7(18): 2561-2562. 何华，刘齐宁，王惠芳等. 中药联合前列腺素E1改善老年2型糖尿病周围神经症状的疗效观察. 中国临床康复，2003; 7(18) :2561~2562.
45. Wu WQ, Liu WF, Xu ML, et al. Clinical Observation of Combined Therapeutic Effect of Lipo-PGE1 and Mecobalam on Diabetic Peripheral Neuropathy. HeBei Medical Journal, 2005.11(5):411-413.
46. Wang L. Clinical Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Anhui Medical Journal, 2004; 25(1) :62-64.
47. Huang CY, Yao WF, Clinical Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Journal of Qiqihar Medical College, 2002; 23(10): 1126-1127.
48. Yao J, Liu W, Observation on Efficacy of PGE1 in Treating Peripheral Neuropathy in diabetes. Journal of Hubei Medical Staff College, 2004; 17(1): 48-50.
49. Wang ZH,, Zhang P, Shen XM, et al. Clinical Study of the Efficacy of PGE1 in the Treatment of Diabeetic Peripheral Neuropathy with 56 participants. Journal of Chinese Physician, 2003; 5(9)1287.
50. Tan YJ, An Z. Efficacy of Lipo-PGE1 injection on Diabetic Nephropathy and Neuropathy. Journal of Chinese-Japan Friendship Hospital, 2004; 18(4) 223-226.
51. Tan ZZ. Clinical Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy with 40 participants. Journal of Practical Nervous Diseases, 2004; 7(6): 78-79.
52. Liu YL, Xiao XL, Liu JH, et al, Observation on Efficacy of. Lipo-PGE1 in Treating Peripheral Neuropathy in diabetes with 32 participants. Journal of NanHua University (Medical Edition), 2001; 29(6):584-585.
53. Hao JP, Yan WS, Zeng WX, et al. Observation of Combined Therapeutic Effect of Lipo-PGE1 and Mecobalam on Diabetic Peripheral Neuropathy with 40 participants. New Chinese Medicine. 2004; 35(9):545-547.
54. Xu WH, Wan CX, Zhang HX, et al. Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy with 20 participants. Herald of Medicine, 2001; 20(12): 755-756.
55. Ying WC, Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Zhejiang Clinical Medical Journal, 2002; 4(12): 913-914.
56. Zhong GL, Lv WM, A Clinical Observation of Lipo-PGE1 and Mecobalamin in the Treatment of Diabetic Peripheral Neuropathy. Journal of Gannan Medical College. 2002, 22(4): 343-345.
57. Wei ZW, Yang HY. A Clinical Observation of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Liaoning Journal of Practical Diabetology. 2003.11(1):35-36.
58. Mo W, Wang JY. Alprostadil in treating Diabetic Peripheral Neuropathy in the elderly. Chongqing Medical Journal, 2003;32(9): 1272-1273.
59. Liang GX, Wu WY, Clinical Study of the Efficacy of PGE1 in the Treatment of Diabetic Painful Neuropathy. Journal of Guangzhou Medicine, 2003; 34(5): 44-45.
60. ` Mi YQ, Liu y, Lin HR, et al. Therapeutic Effect of Lipo-PGE1 on Diabetic Peripheral Neuropathy with 30 participants. Chinese Remedies and Clinics. 2004; 4(5): 371-372.
61. Zhang XK. Alprostadil in treating Diabetic Peripheral Neuropathy with 22 participants. Heilongjiang Medical Journal, 2004; 28(6): 419-421.
62. Li XF, Su RT, Observation of Combined Therapeutic Effect of Lipo-PGE1 and Mecobalam on Diabetic Peripheral Neuropathy. Youjiang Medical Journal. 2004; 35(3):54-55.
63. Wu XX, Huang ZY, Clinical Study of PGE1 in the Treatment of Diabetic Neuropathy. China Synthetical Medicine, 2002, 3(4) :338-339.
64. ` Yu F, Liu GL, Li WJ. A Clinical Observation of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Journal of Medical Theory and practice, 2004; 8(17): 903-904.
65. Liu J, Zhang Y, Xi P. Study of the Efficacy of PGE1 in the Treatment of Diabetic Peripheral Neuropathy. Clinical Medicine of China, 2004; 11(20):1003-1005.
66. Low PA. Autonomic neuropathies. Curr Opin Neurol, 2002; 15(5): 605-609.
67. Zochodne DW. Nerve and ganglion blood flow in diabetes: an appraisal. Int Rev Neurobio, 2002; (50): 161-202.
68. Meyer FP. Polyneuropathy–therapy. Dtsch Med Wochenschr. 2003; 128(11): 572.
69. Shindo H, Tawata M, Inoue M, et al. The effect of prostaglandin E1 CD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy. Diabetes Res Clin Pract, 1994, 24(3):173-180.
70. Carlson LA, Olsson AG. Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet, 1976; 9(7886):810.
71. Zhong HJ, Han XY, Fang YC, et al. Study of the Efficacy of Lipo-PGE1 in the Treatment of Diabetic Peripheral Neuropathy Journal of Practical Diabetology, 1994; 2(1): 33-34.
72. Yasutoshi I, Tadashi Y. The therapeutic effect of Lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors. Prostaglandins and other Lipid Mediators, 2001; (66): 221-234-667.
73. Watanabe T, Kaji R, Oka N, et al. Ultra-high dose methyl-cobalamin promotes nerve regeneration in experimental acrylamide neuropathy. J neurol Sci, 1994; 122(2): 140-143.
74. Zhang SP, A Clinical Study of Methycobal in the Treatment of Diabetic Peripheral Neuropathy. Chinese Journal of Endocrinology and Metabolism, 1998; 14(2): 130.
75. Dyck PJ, Obrien PC. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care, 1989; 12(9): 649-652.
76. Nagai Y, S μgiyama Y, Abe T, et al. 4-g Monofilament is clinically useful for detecting diabetic peripheral neuropathy. Diabetes Care, 2001; 24(1): 183-184.

Chinese Journal of Evidence-Based Medicine

Prostaglandin E1 for Diabetic Peripheral Neuropathy: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Format

Content